Sandro Pignata

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

Isabelle Ray‐Coquard, Patricia Pautier, Sandro Pignata et al. · New England Journal of Medicine · 2019 · 1.9K citations · Full text

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.8K citations

Brca1/2 Mutation, Medicine, Cancer Management +10

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Robert L. Coleman, Amit M. Oza, Domenica Lorusso et al. · The Lancet · 2017 · 1.7K citations · Full text

Rucaparib Maintenance Treatment, Medicine, Recurrent Ovarian Carcinoma +7

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

Nicoletta Colombo, Cristiana Sessa, Andreas du Bois et al. · Annals of Oncology · 2019 · 1.1K citations · Full text

Borderline Tumours, Tumoral Pathology, Medicine +9

Radiofrequency Ablation of Unresectable Primary and Metastatic Hepatic Malignancies

Steven A. Curley, Francesco Izzo, Paolo Delrio et al. · Annals of Surgery · 1999 · 1.1K citations · Full text